Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Vaccines

Free Subscription 24.03.2025 2 BMC Pediatr 1 J Infect 3 J Infect Dis 1 J Pediatr 4 J Virol 1 Lancet 1 Nat Med 1 Pediatr Infect Dis J 6 PLoS One 1 Proc Natl Acad Sci U S A 21 Vaccine 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Pediatr

1. LI Y, Jian B, Kang X, Zhang M, et al
   Clinical features and long-term outcomes of children with pneumococcal meningitis in China: a 10-year single-centre retrospective analysis.
   BMC Pediatr. 2025;25:205.
   PubMed         Abstract available
   
   
2. SEM S, Sarfo JO, Amoadu M, Hormenu T, et al
   Uptake and determinants of routine vaccines among children aged 12-23 months in adansi South district of Ghana. a cross-sectional study.
   BMC Pediatr. 2025;25:198.
   PubMed         Abstract available
   
   

   
   J Infect

3. PEREZ CM, Ruiz-Rius S, Ramirez-Morros A, Vidal M, et al
   Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
   J Infect. 2025 Mar 18:106473. doi: 10.1016/j.jinf.2025.106473.
   PubMed         Abstract available
   
   

   
   J Infect Dis

4. FUJI N, Salamone FN, Kaur R, Bajorski P, et al
   Eighteen Year Longitudinal Study of Uncomplicated and Complex Acute Otitis Media during the Pneumococcal Conjugate Vaccine Era, 2006-2023.
   J Infect Dis. 2025 Mar 20:jiaf154. doi: 10.1093.
   PubMed         Abstract available
   
   
5. MENG Y, Lin Y, Xiong W, Lau EHY, et al
   Effective Real-time Transmission Estimations Incorporating Population Viral Load Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
   J Infect Dis. 2025;231:684-691.
   PubMed         Abstract available
   
   
6. CHOCHUA S, Beall B, Lin W, Tran T, et al
   The emergent invasive serotype 4 ST10172 strain acquires vanG type vancomycin-resistance element: A case of a 66-year-old with bacteremic pneumococcal pneumonia.
   J Infect Dis. 2024 Aug 8:jiae393. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Pediatr

7. ALAYARI A, Ziniel SI, Hawkins E, Mackenzie J, et al
   Evaluation of an Influenza Vaccination Program in the Pediatric Emergency Department.
   J Pediatr. 2025 Mar 17:114541. doi: 10.1016/j.jpeds.2025.114541.
   PubMed         Abstract available
   
   

   
   J Virol

8. PARK H, Kingstad-Bakke B, Cleven T, Jung M, et al
   Diversifying T-cell responses: safeguarding against pandemic influenza with mosaic nucleoprotein.
   J Virol. 2025 Feb 3:e0086724. doi: 10.1128/jvi.00867.
   PubMed         Abstract available
   
   
9. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
   Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
   J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
   PubMed         Abstract available
   
   
10. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed         Abstract available
    
    
11. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed         Abstract available
    
    

    
    Lancet

12. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
    Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
    Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
    PubMed         Abstract available
    
    

    
    Nat Med

13. RUDMAN SPERGEL AK, Ananworanich J, Guo R, Deng W, et al
    mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial.
    Nat Med. 2025 Mar 18. doi: 10.1038/s41591-025-03591.
    PubMed         Abstract available
    
    

    
    Pediatr Infect Dis J

14. FALLACH N, Lasalvia P, Pawaskar M, Chodick G, et al
    Impact of Universal Varicella Vaccination in Israel: A Time-Series Analysis, 2003 to 2020.
    Pediatr Infect Dis J. 2025 Mar 19. doi: 10.1097/INF.0000000000004787.
    PubMed         Abstract available
    
    

    
    PLoS One

15. TAYLOR-ABDULAI HB, Dzantor EK, Mensah NK, Asumah MN, et al
    Coronavirus disease 2019 (COVID-19) vaccine acceptability in Ghana: An urban-based population study.
    PLoS One. 2025;20:e0319798.
    PubMed         Abstract available
    
    
16. ANTEHUNEGN TESEMA G, Sarfo M, Okeke SR, Ameyaw EK, et al
    Unveiling the Drivers of Polio Vaccine Uptake: Insights from a Multi-Country Study of 37 Nations in Sub-Saharan Africa.
    PLoS One. 2025;20:e0316884.
    PubMed         Abstract available
    
    
17. ALAHMADI S, Hoyle R, Head M, Brede M, et al
    Modelling the mitigation of anti-vaccine opinion propagation to suppress epidemic spread: A computational approach.
    PLoS One. 2025;20:e0318544.
    PubMed         Abstract available
    
    
18. BAAKLINY M, Ghosn N, Saleh N, Maison P, et al
    Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.
    PLoS One. 2025;20:e0318344.
    PubMed         Abstract available
    
    
19. SAHA S, Millier M, Samaranayaka A, Edmonds L, et al
    Immunogenicity and safety of measles-mumps-rubella vaccine delivered by the aerosol, intradermal and intramuscular routes in previously vaccinated young adults: a randomized controlled trial protocol.
    PLoS One. 2025;20:e0318893.
    PubMed         Abstract available
    
    
20. ZUBAIR A, Al-Emam A, Ali M, Hussain SM, et al
    Targeting HIV-1 conserved regions: An immunoinformatic pathway to vaccine innovation for the Asia.
    PLoS One. 2025;20:e0317382.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

21. GAILLETON R, Mathew NR, Reusch L, Schon K, et al
    Ectopic germinal centers in the nasal turbinates contribute to B cell immunity to intranasal viral infection and vaccination.
    Proc Natl Acad Sci U S A. 2025;122:e2421724122.
    PubMed         Abstract available
    
    

    
    Vaccine

22. CRAWLEY AW, Murphy K, Plumb ID, Ocansey GA, et al
    Challenges and enablers to establishing COVID-19 vaccine effectiveness studies in the World Health Organization Africa region: A mixed-methods evaluation of the African region monitoring vaccine effectiveness (AFRO-MoVE) network.
    Vaccine. 2025 Mar 20:126823. doi: 10.1016/j.vaccine.2025.126823.
    PubMed         Abstract available
    
    
23. HAMID S, Simeone RM, Newhams MM, Halasa N, et al
    Concordance between parent-reported and documented COVID-19 vaccination status among hospitalized children and adolescents: Implications for vaccine effectiveness estimates, May 2021-October 2023.
    Vaccine. 2025;54:126891.
    PubMed         Abstract available
    
    
24. ILIYASU Z, Danzomo AA, Jeyaseelan V, Gofama MM, et al
    Impact of novel Oral Poliovirus Type 2 vaccination campaigns: A seroprevalence survey in Nigeria, 2022.
    Vaccine. 2025;54:126978.
    PubMed        
    
    
25. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    PubMed         Abstract available
    
    
26. RASKIN N, Hiligsmann M, Luyten J, Tubeuf S, et al
    Socio-demographic differences in citizen' preferences for distributing a scarce, lifesaving resource: A case study using COVID-19 vaccine distribution in Belgium.
    Vaccine. 2025;55:126997.
    PubMed         Abstract available
    
    
27. NAZIAT H, Rahman MH, Das RC, Islam M, et al
    Impact of 10-valent pneumococcal conjugate vaccine on the epidemiology of otitis media with otorrhea among Bangladeshi children.
    Vaccine. 2025;55:126995.
    PubMed         Abstract available
    
    
28. CHOI J, Feelemyer J, Choe K, Lynch K, et al
    Anti-vaccine attitudes and COVID-19 vaccine status at the end of the U.S. public health emergency.
    Vaccine. 2025;55:127003.
    PubMed         Abstract available
    
    
29. FIRTH C, Emary K, Stuart A, Browne R, et al
    Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.
    Vaccine. 2025;54:127013.
    PubMed         Abstract available
    
    
30. LU H
    Generative AI for vaccine misbelief correction: Insights from targeting extraversion and pseudoscientific beliefs.
    Vaccine. 2025;54:127018.
    PubMed         Abstract available
    
    
31. RICCI L, Fery C, Tubach F, Agrinier N, et al
    Health care institutions and their physicians are the greatest promoters of COVID-19 vaccine acceptance among health care workers.
    Vaccine. 2025;54:127005.
    PubMed         Abstract available
    
    
32. MYBURGH L, Karsjens H, Blanas A, de Ligt A, et al
    Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine.
    Vaccine. 2025;54:126989.
    PubMed         Abstract available
    
    
33. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    PubMed         Abstract available
    
    
34. XU J, Davoudpour S, Phillips G 2nd
    Applying the health belief model (HBM) to understand COVID-19 vaccine uptake among youth and young adults: Findings from a 6-month follow-up study in the United States.
    Vaccine. 2025;54:127002.
    PubMed         Abstract available
    
    
35. ZHANG X, Zhao T, Cai X, Zhang W, et al
    Are health education effective to improve herpes zoster vaccine willingness in vulnerable elderly.
    Vaccine. 2025;54:126975.
    PubMed         Abstract available
    
    
36. YUILL S, Hall MT, Caruana M, Lui G, et al
    Predicted impact of HPV vaccination and primary HPV screening on precancer treatment rates and adverse pregnancy outcomes in Australia 2010-2070: Modelling in a high income, high vaccination coverage country with HPV-based cervical screening.
    Vaccine. 2025;54:126986.
    PubMed         Abstract available
    
    
37. YANAI T, Yoshida S, Kawakami K
    Gastroenteritis hospitalizations over 19 years before and after introduction of rotavirus vaccine in Japan: A nationwide claims database.
    Vaccine. 2025;55:127027.
    PubMed         Abstract available
    
    
38. MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
    Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
    Vaccine. 2025;55:127014.
    PubMed         Abstract available
    
    
39. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    PubMed         Abstract available
    
    
40. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    PubMed         Abstract available
    
    
41. MPABALWANI EM, Sakala C, Kamiji E, Simwaka J, et al
    Challenges and lessons learned during the switching of rotavirus vaccine from Rotarix to Rotavac in Zambia.
    Vaccine. 2025;55:127012.
    PubMed         Abstract available
    
    
42. BALDOLLI A, Fournier A, Roger H, Piednoir E, et al
    Implementation of school-based vaccination in French middle schools: Efficient or not?
    Vaccine. 2025;55:127007.
    PubMed         Abstract available
    
    

    
    Virology

43. SUZUKI Y
    Application of reverse genetics system to Chikungunya virus study.
    Virology. 2025;605:110465.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.